Homocysteine in Vascular Behçet Disease: A Meta-Analysis

Objective—Behçet disease (BD) is a vasculitis of unknown etiology, characterized by oral or genital aphtosis and uveitis. Homocysteine (hcy) is an independent risk factor for venous and arterial thrombosis. The association between hyperhomocysteinemia and thrombosis has been investigated in some studies in BD patients. However, information on this association is based only on the results of small studies with conflicting results. To overcome such limitations, we performed a metaanalysis comparing the plasma levels of hcy in BD patients with and without history of thrombosis. Methods and Results—We searched for all published studies using the Medline and Embase databases. Two reviewers performed study selection independently. Studies were included if hcy was measured in adult BD patients with and without thrombosis. Two reviewers independently extracted data on study and population characteristics. The mean value of hcy in BD patients and the presence of hyperhomocysteinemia in patients with and without thrombosis were collected. Association between thrombosis and hyperhomocysteinemia, and the mean difference of hcy levels in BD patients with and without thrombosis were calculated. Sixteen studies, for a total of 979 patients, were included. Hyperhomocysteinemia was more prevalent in patients with thrombosis than in those without (odds ratio 3.14; 95% CI 1.26 to 7.80) Mean levels of hcy were significantly higher in patients with thrombosis in comparison with patients without (mean difference 3.30 &mgr;mol/L; 95% CI 2.09 to 4.51). Conclusion—Our results suggest that hyperhomocysteinemia may be considered to be associated with thrombosis in BD patients.

[1]  L. Weinehall,et al.  Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function , 2009, Journal of internal medicine.

[2]  A. Akgul,et al.  Homocysteine May Involve in the Pathogenesis of Behcet's Disease by Inducing Inflammation , 2009, Mediators of inflammation.

[3]  N. Düzgün,et al.  Thymidylate synthase genotype and serum concentrations of homocysteine and folate in Behçet’s disease , 2008, Clinical Rheumatology.

[4]  M. Nazarinia,et al.  Serum homocystein level and vascular thrombosis in patients with Behçet disease , 2007 .

[5]  M. Khanfir,et al.  Does lowering hyperhomocysteinemia by folic acid beneficial for oculo-Behcet's disease? A pilot study. , 2007, La Tunisie medicale.

[6]  F. Rosendaal,et al.  No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. , 2007, Archives of internal medicine.

[7]  H. Blom,et al.  Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. , 2004, Blood.

[8]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[9]  D. Corella,et al.  Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events , 2006, Thrombosis and Haemostasis.

[10]  N. Z. Cantürk,et al.  Effect of Helicobacter pylori infection on deep vein thrombosis seen in patients with Behçet's disease. , 2006, East African medical journal.

[11]  M. Kayıkçıoğlu,et al.  Endothelial functions in Behçet’s disease , 2006, Rheumatology International.

[12]  F. Sofi,et al.  Thrombophilic risk factors for symptomatic peripheral arterial disease. , 2005, Journal of vascular surgery.

[13]  S. Pay,et al.  Hyperhomocysteinemia in patients with Behçet’s disease: is it due to inflammation or therapy? , 2005, Rheumatology International.

[14]  L. Matri,et al.  Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behçet's disease , 2004, Clinical chemistry and laboratory medicine.

[15]  Thomas McGinn,et al.  Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic) , 2004, Canadian Medical Association Journal.

[16]  M. Ehrenfeld,et al.  Thrombophilic factors are not the leading cause of thrombosis in Behçet’s disease , 2004, Annals of the rheumatic diseases.

[17]  F. España,et al.  Activated protein C levels in Behçet's disease and risk of venous thrombosis , 2004, British journal of haematology.

[18]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[19]  R. Becker,et al.  Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. , 2003, American heart journal.

[20]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[21]  K. Tanriverdi,et al.  Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet's disease , 2003, Rheumatology International.

[22]  M. Hsairi,et al.  Does hyperhomocysteinemia increase the risk of thrombosis in Behçet's disease? , 2003, Advances in experimental medicine and biology.

[23]  M. Duman,et al.  Serum homocysteine level is higher in Behçet’s disease with vascular involvement , 2003, Rheumatology International.

[24]  C. Zouboulis.  Adamantiades-Behçet’s Disease , 2003, Advances in Experimental Medicine and Biology.

[25]  B. Zappacosta,et al.  Comparing Different Methods for Homocysteine Determination , 2002, Clinical chemistry and laboratory medicine.

[26]  F. Şahin,et al.  Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome? , 2002, Clinical and experimental rheumatology.

[27]  I. Haznedaroglu,et al.  Hemostatic parameters in Behçet's disease: a reappraisal , 2002, Rheumatology International.

[28]  Sang-Woon Choi,et al.  Coagulation parameters and plasma total homocysteine levels in Behcet's disease. , 2002, Thrombosis research.

[29]  I. Haznedaroglu,et al.  Pathological haemostasis and "prothrombotic state" in Behçet's disease. , 2002, Thrombosis research.

[30]  M. Margaglione,et al.  Combined Effect of Factor V Leiden and Prothrombin 20210A on the Risk of Venous Thromboembolism , 2001, Thrombosis and Haemostasis.

[31]  Jonathan A C Sterne,et al.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.

[32]  K. Aksu,et al.  Hyperhomocysteinaemia in Behçet's disease. , 2001, Rheumatology.

[33]  E. Falk,et al.  Homocysteine and atherothrombosis , 2001, Lipids.

[34]  O. Ozcebe,et al.  Behçet's disease. , 2019, The New England journal of medicine.

[35]  L. Tokgözoğlu,et al.  Hyperhomocysteinaemia and activated protein C resistance in Behçet’s disease , 2000, Journal of internal medicine.

[36]  S. Midorikawa,et al.  Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from vascular endothelial and smooth muscle cells. , 2000, Biochemical and biophysical research communications.

[37]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[38]  D. Steinberg,et al.  Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[39]  H. Blom,et al.  Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[40]  D. Hayoz,et al.  [Homocysteine and venous thromboembolism]. , 1997, Schweizerische medizinische Wochenschrift.

[41]  P. Harpel,et al.  Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis. , 1996, The Journal of nutrition.

[42]  P. Reitsma,et al.  Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. , 1996, The New England journal of medicine.

[43]  K. Shimada,et al.  Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. , 1993, The Journal of clinical investigation.

[44]  E. Kansu,et al.  Vascular involvement in Behçet's disease. , 1992, The Journal of rheumatology.

[45]  W. Willett,et al.  Misinterpretation and misuse of the kappa statistic. , 1987, American journal of epidemiology.

[46]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[47]  A. Silman,et al.  [Criteria of diagnosis of Behcet's disease]. , 1975, La Tunisie medicale.

[48]  Gray Gs.  The triple complex syndrome of Behcet. , 1950 .

[49]  G. Gray.  The triple complex syndrome of Behcet. , 1950, Canadian Medical Association journal.